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Effectiveness and safety of topical 
levodopa in a chick model of 
myopia
Kate Thomson  1*, Cindy Karouta1, Ian Morgan2, Tamsin Kelly3 & Regan Ashby1,2
Animal models have demonstrated a link between dysregulation of the retinal dopamine system and 
the excessive ocular growth associated with the development of myopia. Here we show that intravitreal 
or topical application of levodopa, which is widely used in the treatment of neurological disorders 
involving dysregulation of the dopaminergic system, inhibits the development of experimental 
myopia in chickens. Levodopa slows ocular growth in a dose dependent manner in chicks with a 
similar potency to atropine, a common inhibitor of ocular growth in humans. Topical levodopa remains 
effective over chronic treatment periods, with its effectiveness enhanced by coadministration with 
carbidopa to prevent its premature metabolism. No changes in normal ocular development (biometry 
and refraction), retinal health (histology), or intraocular pressure were observed in response to chronic 
treatment (4 weeks). With a focus on possible clinical use in humans, translation of these avian safety 
findings to a mammalian model (mouse) illustrate that chronic levodopa treatment (9 months) does not 
induce any observable changes in visual function (electroretinogram recordings), ocular development, 
and retinal health, suggesting that levodopa may have potential as a therapeutic intervention for 
human myopia.
Myopia, or short-sightedness, is a refractive disorder arising from a mismatch between the optical power of 
the eye and its axial length. This is due to excessive elongation of the eye during development and into young 
adulthood which leads to the focal plane of distant objects falling in front of the retina, instead of on it, causing 
the image to appear blurred. Myopia is now recognised as a leading cause of visual impairment and low vision 
world-wide1. Over the past 50 years, myopia rates have increased dramatically, with some estimates predicting 
that half of the world’s population could be affected by short-sightedness by 20501. The rapid rise in myopia 
prevalence is most evident in educationally developed areas of East and Southeast Asia (for review see2). In these 
locations, the prevalence of myopia in young adults has risen from 20–30% to 80–85% over one generation2,3. 
Over the same period, the prevalence of high myopia has increased from 1–2% to 10–20%2.
These changes in prevalence pose two main challenges. The first is the need to provide optical or other cor-
rections for the associated refractive error for a large percentage of the population. Arguably an even greater 
challenge comes from the increased prevalence of high myopia, and its associated sight-threatening pathological 
changes4. Correction of the refractive error does not prevent the development of these conditions, the chances 
of which increase with the severity of myopia, as it does not address the excessive elongation of the eye4. Such 
pathologies include chorio-retinal changes including retinal detachments, myopic macular degeneration, and 
staphyloma, as well as an increased risk of other sight-threatening conditions such as glaucoma and cataracts (for 
review see5). The US National Eye Institute has estimated the annual cost for treating refractive disorders in the 
US alone at just under $14 billion in 2010 and rising6, with considerable indirect costs such as lost productivity 
unaccounted for. The social returns to be obtained through myopia prevention are therefore significant. For this 
reason, a deeper understanding of how ocular growth is regulated, and the development of preventive interven-
tions to slow the onset or progression of myopia, are urgently needed.
Animal studies have demonstrated that ocular growth is regulated locally in response to visual stim-
uli by pathways originating in the retina, with the retinal transmitter dopamine playing a key role (for review 
see7,8). Dopamine release is strongly affected by light and the spatiotemporal properties of visual inputs, with 
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dysregulation of the dopaminergic system heavily implicated in the development of experimental myopia (for 
review see7,8). Specifically, in multiple species, retinal dopamine synthesis and release has been shown to be sig-
nificantly down-regulated during the development of experimental myopia9–13, whilst pharmacological adminis-
tration of dopamine agonists, which mimic the effects of dopamine, have been shown to inhibit the development 
of experimental myopia (for review see7). Furthermore, intravitreal administration of exogenous dopamine in 
rabbits14 and systemic administration of its precursor levodopa (L-DOPA) in guinea pigs15 inhibit the develop-
ment of experimental myopia, while retina-specific tyrosine hydroxylase knockout mice and mice treated with 
6-hydroxydopamine, which depletes the retina of dopaminergic neurons, show a myopic shift in refraction13,16. 
Finally, dopaminergic activity appears to underly the mechanism by which bright light exposure, or exposure to 
brief periods of normal vision, prevents the development of experimental myopia, specifically form-deprivation 
myopia (FDM), in the chick17–27.
Based on the potential role of dopamine in the regulation of ocular growth, this article investigates whether 
topical administration of levodopa, a drug widely used to treat neurological disorders involving dopaminergic 
disfunction28, can inhibit ocular growth and therefore prevent the development of experimental myopia in an 
animal model (chicken). Here we show that levodopa slows ocular growth and inhibits experimental myopia in 
a dose-dependent manner in chicks with a similar potency to atropine, whilst not affecting ocular health across 
those parameters tested following chronic administration. For translational potential, this avian safety data was 
further complemented in a second, mammalian, model by analysing the effects of chronic levodopa treatment on 
ocular safety in mice.
Results
Effectiveness of levodopa in preventing experimental myopia in chickens. Intravitreal injections 
inhibit form-deprivation myopia in a dose dependent manner. To investigate whether levodopa inhibits experi-
mental myopia when introduced directly to the retina, levodopa was administered to chicks undergoing FDM as 
a daily intravitreal injection at one of four concentrations (0.15 mM, 1.5 mM, 15 mM, and 75 mM; Supplementary 
Table S-1A) for four days.
Ocular biometry: Ocular growth in untreated contralateral control eyes was not affected by intravitreal 
injection of levodopa, with no significant difference in axial length observed between contralateral control 
and age-matched untreated control eyes following 4 days of treatment (ANOVA, F(5, 84) = 0.284, p = 0.921). 
As expected, form-deprivation (FD, myopia induction) induced a significantly greater rate of axial elongation 
in diffuser-treated eyes relative to that seen in contralateral control or age-matched untreated control eyes 
over the four-day treatment period (p < 0.001, Fig. 1A, Supplementary Table S-2). This excessive elongation 
Figure 1. Dose Response Curve – Levodopa Intravitreal Injections. (A) Axial length after four days of 
treatment for each of the tested conditions. (B) Percent protection against the axial elongation associated with 
diffuser wear (FD) relative to levodopa concentration administered. (C) Refractive values after four days of 
treatment for each of the tested conditions. (D) Percent protection against the myopic refractive shift associated 
with FD relative to levodopa concentration administered. Data represent mean ± standard error of the mean. 
FD: Form deprivation. Untreated controls: age-matched untreated controls. Statistics denote difference to FD 
Only; *p < 0.05, **p < 0.02, ***p < 0.001.
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was, however, inhibited in a dose-dependent manner by the daily intravitreal injection of levodopa (ANOVA, 
F(4,68) = 15.072, p < 0.001; Fig. 1A), with the protective effect best described by a logarithmic relationship 
(y = 5.8816In(x) + 109.19, r2 = 0.9848; Fig. 1B), with an EC50 of 0.000043 mg/day (0.0008 mM or 0.0007% w/v). 
All concentrations of levodopa tested induced a significant reduction in axial elongation relative to FDM alone 
(0.15 mM: p < 0.02; 1.5–75 mM: p < 0.001, Fig. 1A).
At all concentrations tested, levodopa did not affect anterior chamber depth (ANOVA, F(5,84) = 1.109, 
p = 0.361) or lens thickness (ANOVA, F(5, 84) = 0.563, p = 0.728), but instead, changes in axial length correlated 
solely with changes in vitreal chamber depth (ANOVA, F(5, 84) = 15.042, P < 0.001).
Daily intravitreal injection of levodopa over a four-day period did not affect normal ocular development when 
administered to otherwise untreated birds (p = 1.000; Supplementary Table S-2), nor did it affect contralateral 
control eyes (ANOVA, F(5, 84) = 0.353, p = 0.879). Furthermore, intravitreal injection of the vehicle solution did 
not prevent the axial elongation associated with FD (p = 1.000).
Refraction: As with axial length, refraction in untreated contralateral control eyes was also not affected 
by intravitreal injection of levodopa, with no significant difference observed between contralateral con-
trol and age-matched untreated control eyes at cessation of treatment (ANOVA, F(5, 84) = 0.454, p = 0.808). 
Form-deprivation induced a significant myopic shift in refraction relative to that seen in contralateral control 
and age-matched untreated control eyes (p < 0.001, Fig. 1C,D, Supplementary Table S-2). This myopic shift was 
inhibited in a dose-dependent manner by the daily intravitreal injection of levodopa (y = 6.0164In(x) + 76.15, 
r2 = 0.9879); Fig. 1D), with greater protection seen with increasing concentrations (Fig. 1C, ANOVA, 
F(4,68) = 21.654, p < 0.001). At all concentrations, treated eyes showed a less myopic refraction compared to that 
observed in FD only chickens (0.15 mM: p < 0.02, 1.5–75 mM: p < 0.001; Fig. 1C), however, all levodopa groups 
still showed a relative myopic shift when compared to age-matched untreated control animals (p < 0.001 in all 
groups; Fig. 1C).
As with axial length, there was no effect on refractive development in contralateral control eyes 
(Supplementary Table S-2; ANOVA, F(5, 84) = 0.665, p = 0.651). Similarly, daily intravitreal injection of levo-
dopa did not affect normal refractive development when administered to otherwise untreated eyes (p = 0.128). 
Intravitreal injection of the vehicle solution alone did not alter myopic refractive development in FD eyes com-
pared to FD only chicks (p = 0.093).
Topical eye drops inhibit form-deprivation myopia in a dose dependent manner. To examine whether levodopa 
is effective at inhibiting FDM when applied topically to the eye, as it is for intravitreal injections, twice-daily eye 
drops of levodopa were administered to chicks undergoing FD at one of four concentrations (0.15 mM, 1.5 mM, 
15 mM, and 45 mM; Supplementary Table S-1B) for four days.
Ocular biometry: As with intravitreal injections, ocular growth in contralateral control eyes was not altered 
by levodopa eye drops, with no significant difference in axial length observed between contralateral control and 
age-matched untreated control eyes at the end of treatment (ANOVA, F(5,101) = 0.454, p = 0.810). Twice-daily 
topical application of levodopa significantly inhibited the excessive axial elongation associated with myopia 
induction in a dose-dependent manner (Fig. 2A, Supplementary Table S-3; ANOVA, F(4,85) = 5.494, p < 0.01). 
This effect was best described by a logarithmic function (y = 7.0442In(x) + 67.381, r2 = 0.9899; Fig. 2B), with an 
EC50 of 0.085 mg/day (2.69 mM or 0.053% w/v). At the highest dose (45 mM), there was no significant differ-
ence in axial length to those values seen in age-matched untreated control eyes (p = 0.186). Like that observed 
for intravitreal injections, topical levodopa treatment, at all concentrations, did not affect anterior cham-
ber depth (ANOVA, F(5,93) = 0.990, p = 0.428) or lens thickness (ANOVA, F(5,93) = 0.741, p = 0.594), but 
rather the changes in axial length observed were associated with changes in vitreal chamber depth (ANOVA, 
F(5,93) = 9.420, p < 0.001; Supplementary Table S-3). Furthermore, analysis of levodopa at 15 mM demonstrated 
no effects on corneal curvature (levodopa treated eyes 3.2 ± 0.6 mm radius of curvature vs contralateral control 
eyes 3.3 ± 0.4 mm radius of curvature; n = 5, p = 0.501) or corneal thickness (levodopa treated eyes 215.9 ± 5.3 µm 
vs contralateral control eyes 214.5 ± 7.5 µm; n = 5, p = 0.400).
Topical application of levodopa did not alter axial development compared to age-matched untreated con-
trols (Supplementary Table S-3) when administered to otherwise untreated chickens (p = 1.000), nor did it affect 
ocular growth in contralateral control eyes (ANOVA, F(5,93) = 1.294, p = 0.273). Topical administration of the 
vehicle solution did not prevent or alter the excessive axial growth associated with FDM (p = 0.285), indicating 
that the presence of levodopa was critical in inhibiting experimental myopia.
Refraction: Consistent with the data presented thus far, levodopa eye drops did not alter the refrac-
tive development of contralateral control eyes relative to age-matched untreated control eyes (ANOVA, F(5, 
101) = 1.438, p = 0.223). Topical administration of levodopa significantly inhibited the negative shift in refrac-
tion associated with FD in a dose-dependent manner (0.15 mM: p < 0.02; 1.5 mM, 15 mM, 45 mM: p < 0.001: 
Fig. 2C,D, Supplementary Table S-3), with the protective effect best described by a logarithmic relationship 
(y = 5.2266In(x) + 41.475, R2 = 0.934; Fig. 2D). However, as with intravitreal injections, topically treated eyes 
still showed a relative myopic shift relative to age-matched untreated chickens (ANOVA, F(4,64) = 149.165, 
p < 0.001).
Refractive development (Supplementary Table S-3) was unaffected in contralateral control eyes of animals 
treated with levodopa (ANOVA, F(5,93) = 0.959, p = 0.448) or in otherwise untreated eyes (p = 1.000). Eye drops 
containing only the vehicle solution did not alter the degree of myopic shift in diffuser-treated eyes (p = 1.000). 
This once again indicates that levodopa, while not altering normal refractive development, was the factor respon-
sible for inhibiting the myopic refractive changes generated by FD.
Modification of bioavailability enhances the potency of topical eye drops. To investigate whether the protective 
effects observed with topical application of levodopa could be enhanced by increasing bioavailability, levodopa 
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eye drops were administered in the presence of carbidopa (4:1 levodopa:carbidopa ratio, to prevent premature 
metabolism), or 10% dimethyl sulfoxide (DMSO, to increase corneal penetration) for a period of four days 
(Supplementary Table S-1B).
The addition of carbidopa, at a 1:4 ratio to levodopa (3.75 mM carbidopa:15 mM levodopa), significantly 
enhanced the protective effects observed relative to levodopa alone against FD for both axial length (94.6% ± 9.73 
protection, p < 0.001; 32.8% increase from levodopa alone, p < 0.02; Fig. 3A, Supplementary Table S-3) 
and refraction (45.6% ± 6.89 protection, p < 0.001; 12.8% increase from levodopa alone, p < 0.001; Fig. 3B, 
Supplementary Table S-3) over a four day period of treatment.
Those animals treated with a levodopa/DMSO solution demonstrated slightly shorter axial lengths than 
those animals treated with levodopa alone (83.1% ± 8.39 protection, p < 0.001; 21.3% increase from levodopa 
alone, p < 0.02; Fig. 3A, Supplementary Table S-3). However, there was no significant difference in the degree to 
which the myopic refractive shift was lessened between levodopa and levodopa/DMSO treated animals (Fig. 3B, 
Supplementary Table S-3).
Levodopa remains effective over chronic treatment periods. To examine whether the protective effects of topical 
levodopa can be maintained over chronic treatment periods, levodopa, levodopa/carbidopa, and levodopa/0.1% 
benzalkonium chloride (BAK, a frequently used ophthalmic alternative to DMSO) solutions were topically 
administered (Supplementary Table S-1B) to chicks undergoing FD for four weeks (approximately one third of 
the ocular maturation period of chicks). At the end of the treatment period ocular samples were examined to 
assess the retina for changes in architecture or signs of apoptosis.
The excessive axial elongation associated with FD was significantly inhibited by levodopa treatment over 4 
weeks compared to FD-only animals (Wilks’ Lambda = 0.425, F(3,32) = 1.816, p < 0.05; Supplementary Table S-4; 
Fig. 4A; 56.9% ± 1.09 protection). This protective effect was enhanced by the addition of carbidopa (levodopa: 
p < 0.01, to levodopa/carbidopa (65.1% ± 1.19 protection): p < 0.001, at week 4, Fig. 4A), but was no more pro-
tective with the addition of 0.1% w/v BAK (levodopa: p < 0.01, to levodopa/BAK (51.62% ± 1.31 protection) 
p = 0.14, Fig. 4A). Levodopa, levodopa/carbidopa, or levodopa/BAK did not alter anterior chamber depth 
(Wilks’ Lambda = 0.602, F(3, 32) = 0.938, p = 0.517) or lens thickness (Wilks’ Lambda = 0.579, F(3, 32) = 1.638, 
p = 0.126) over 4 weeks of treatment (Supplementary Table S-4). Hence all ocular changes observed arose through 
changes in vitreal chamber depth (Wilks’ Lambda = 0.453, F(3,32) = 1.911, p < 0.05).
In accordance with axial length changes, long-term topical treatment significantly inhibited the myopic 
shift in refraction seen in response to FD (Wilks’ Lambda = 0.078, F(3,32) = 7.569, p < 0.001; Supplementary 
Figure 2. Dose Response Curve – Levodopa Topical Eye Drops. (A) Axial length after four days of treatment 
for each tested condition. (B) Percent protection against the axial elongation associated with form-deprivation 
(FD) relative to amount of levodopa administered. (C) Refractive values after four days of treatment for each 
tested condition. (D) Percent protection against the myopic refractive shift associated with FD relative to 
amount of levodopa administered. Data represents mean ± standard error of the means FD: Form deprivation. 
Untreated controls: age-matched untreated controls. Statistics denote difference to FD Only; *p < 0.05, 
**p < 0.02, ***p < 0.001.
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Table S-5; Fig. 4B), with all treated animals exhibiting significantly less myopic refractions than FD-only treated 
animals at week 4 (all groups: p < 0.001), and no significant difference between treatment groups (levodopa 
(65.6% ± 5.36 protection) vs levodopa:carbidopa (66.4% ± 8.36 protection): p = 1.000; levodopa vs levodopa/
BAK (45.5% ± 4.03 protection): p = 0.530, levodopa/BAK vs levodopa:carbidopa: p = 0.340).
Administration of levodopa, levodopa/carbidopa, or levodopa/BAK drops to otherwise untreated eyes 
(unoccluded contralateral eyes were treated in long term experiments) did not result in any alteration in axial 
elongation (Wilks’ Lambda = 0.350, F(3,25) = 1.716, p = 0.074; Supplementary Table S-4) or refraction (Wilks’ 
Lambda = 0.362, F(3,25) = 1.650, p = 0.090; Supplementary Table S-5) relative to age-matched untreated controls. 
Similarly, treatment did not alter corneal thickness (ANOVA, F(3, 32) = 1.189, p = 0.339) or intraocular pressure 
(ANOVA, F(3, 32) = 1.355, p = 0.285; Supplementary Table S-6).
Levodopa treatment does not induce structural changes in retinal architecture or induce retinal cell apoptosis in 
chickens. Daily treatment with levodopa (15 mM; Supplementary Figure S-1C & 6E), levodopa:carbidopa 
(15 mM:3.75 mM; Supplementary Figure S-1 D & 6F), or levodopa:BAK (15 mM in 0.1%; Supplementary 
Figure S-1 E & 6G) drops over four weeks induced no observable changes in retinal structure or architecture 
(Supplementary Figure S-1), or observable signs of apoptosis (Supplementary Figure S-2), relative to that seen in 
FD or age-matched untreated control eyes (Supplementary Figures S-1 A & S-2 C).
Levodopa increases dopamine synthesis and release within the eye. To investigate whether levodopa admin-
istration increases dopamine synthesis and release within the eye, levels of levodopa, dopamine, and 
3,4-dihydroxyphenylacetic acid (DOPAC) were measured in vitreal samples from chicks undergoing one of the 
following treatments: no treatment, FD, and FD with intravitreal injection of levodopa (15 mM). Samples were 
collected 1 hours into the light phase, which represented 1 hour of treatment. Measures of levodopa, dopamine 
and DOPAC levels were undertaken via liquid chromatography – mass spectrometry (LC-MS).
In FD eyes, levodopa (Fig. 5A) and dopamine (Fig. 5B) levels in the vitreous were lower, but not statistically, 
than that of age-matched untreated controls. The loss of statistical significance was due to the levels of both 
Figure 3. Topical Eye Drops – Modification of Bioavailability. (A) Axial length measurements following four 
days of treatment for each tested condition. (B) Refraction following four days of treatment for each tested 
condition. Data represents mean ± standard error of the mean. FD: Form deprivation. Untreated controls: age-
matched untreated controls. DMSO: Dimethyl sulfoxide. Statistics denote difference to FD Only; *p < 0.05, 
**p < 0.02, ***p < 0.001.
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molecules falling below the quantification signal to noise cut-off (S/N 10, LOQ (dopamine: 0.28pmol/vitreous, 
levodopa: 1.3pmol/vitreous, DOPAC: 8.4pmol/vitreous)) in multiple samples, as such, statistics were only per-
formed on those values falling above the signal to noise cut-off. Vitreal DOPAC however (Fig. 5C) was sig-
nificantly lower in FD eyes compared to age matched untreated controls (p < 0.001). In FD eyes treated with 
intravitreal injections of 15 mM levodopa, vitreal levels of levodopa, dopamine, and DOPAC were substantially 
elevated compared to both age-matched untreated controls (p < 0.01, p < 0.05 and p < 0.01 respectively) and FD 
treated eyes (p < 0.01, p < 0.05 and p < 0.001 respectively).
Topical levodopa administration does not significantly alter levels of dopamine or its metabolites within the 
blood. To establish whether topical administration of levodopa increases systemic dopaminergic activity, lev-
odopa, dopamine, DOPAC and homovanillic acid (HVA) levels were analysed by LC-MS in blood samples from 
untreated and levodopa treated chicks 15 minutes after administration. Blood from untreated animals was also 
spiked with levodopa and analysed by LC-MS immediately and after 15 minutes to simulate the maximal change 
expected if levodopa was systemically distributed.
Direct spiking of a 15 mM levodopa solution into blood from untreated animals significantly increased lev-
odopa (Fig. 6A) and dopamine (Fig. 6B) levels compared to age-matched untreated controls (levodopa: 0 min-
utes, p < 0.05; 15 minutes, p < 0.001, dopamine: 0 minutes, p < 0.05; 15 minutes, p < 0.01). Whereas topically 
applied levodopa (15 mM) did not result in any significant change in blood levodopa (p = 0.749) or dopamine 
levels (p = 0.294) from that of untreated controls. Blood from animals treated with topically applied levodopa 
significantly differed from both 0 (levodopa: p < 0.001, dopamine: p < 0.05) and 15 minute (levodopa: p < 0.001, 
dopamine: p < 0.001) spike simulations. In a number of samples, levodopa levels within untreated and drops 
treated animals fell below the quantification signal to noise cut-off (S/N 10, LOQ (dopamine: 5.4 ng/mL, levo-
dopa: 170 ng/mL)), with levels well below spiked samples indicating that topically applied levodopa shows limited 
systemic distribution. In all groups, DOPAC and HVA were not quantifiable (S/N < 10).
Levodopa is of comparable effectiveness to atropine. To compare the effectiveness of levodopa in slowing ocular 
growth to that of atropine, the primary pharmacological treatment currently used for myopia in humans, intra-
vitreal and topical application of atropine was tested over four days in an equivalent manner to that of levodopa 
(Supplementary Table S-1D & E).
Figure 4. Long-term effectiveness of 15 mM levodopa drops. (A) Weekly axial length measurements for 
form deprived, drug treated eyes. (B) Weekly refraction for form deprived, drug treated eyes. Data represents 
mean ± standard error of the mean. BAK: Benzalkonium chloride. FD: Form deprivation. Untreated controls: 
age-matched untreated controls.
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Intravitreal levodopa and atropine showed similar dose-dependent protection against the excessive axial 
growth associated with FD (levodopa vs FDM: ANOVA, F(4,68) = 15.072, p < 0.001; atropine vs FDM: ANOVA 
(5, 81) = 7.895, p < 0.001; atropine vs levodopa: p = 0.84; Fig. 7A; Supplementary Table S-2 and S-7). However, 
intravitreal levodopa showed a greater effectiveness against the myopic refractive shift associated with FD (lev-
odopa vs FDM: ANOVA, F(4,68) = 21.654, p < 0.001; atropine vs FDM: ANOVA (5,81) = 11.535, p < 0.001; lev-
odopa vs atropine: p < 0.001; Fig. 7B). Both compounds showed similar EC50 values against the axial elongation 
associated with FD (levodopa: 0.0007% w/v, atropine: 0.0001% w/v), with their effects best described by a loga-
rithmic relationship (levodopa: y = 6.9542ln(x) + 100.39, atropine: y = 4.96ln(x) + 95.209).
Topical levodopa was slightly more effective than topical atropine at inhibiting axial elongation (levodopa vs 
FDM: ANOVA, F(4,85) = 5.494, p < 0.01; atropine vs FDM: ANOVA (4,46) = 3.632, p < 0.02; atropine vs levo-
dopa: p < 0.05; Fig. 7C; Supplementary Table S-3 and S-7) and myopic shifts in refraction (levodopa vs FDM: 
ANOVA, F(4,64) = 149.165, p < 0.001; atropine vs FDM: ANOVA (4,46) = 3.922, p < 0.001; atropine vs levodopa: 
p < 0.05; Fig. 7D). Both compounds showed similar EC50 values against the axial elongation associated with FD 
(levodopa: 0.053% w/v, atropine: 0.060% w/v), with their protection best described by a logarithmic relationship 
(levodopa: y = 7.0094ln(x) + 70.633, atropine: y = 4.1229ln(x) + 61.584).
Figure 5. Vitreal levels of levodopa and its metabolites in form deprived (FD) and levodopa treated chicks. (A) 
Levodopa (B) dopamine (C) 3,4-dihydroxyphenylacetic acid (DOPAC). Data represents the mean ± standard 
error of the mean. Statistics denote difference to FD Only; *p < 0.05, **p < 0.02, ***p < 0.001. TRACE denotes 
when several samples were detected (S/N > 3) but not quantifiable (S/N < 10); levodopa in FD samples fell in 
this range in 4 out of 5 samples and dopamine in FD samples fell in this range in 2 out of 5 samples.
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Long-term safety of levodopa in mice. To examine the ocular safety of levodopa in a mammalian model (mouse), 
complementing the results observed in chicks above, levodopa and levodopa/carbidopa eye drops were adminis-
tered to otherwise untreated C57BL/6 J mice (Supplementary Table S-1E) over a period of 9 months.
No abnormalities were detected in daily health score analysis of treated or untreated mice over 9 months of 
treatment whilst base histology and apoptosis analysis, like chicks, showed no signs of retinal degradation or 
toxicity (data not shown).
Further, normal refractive development (age-matched untreated control males: 6.37 ± 0.17D; females: 
4.82 ± 0.46D) was not altered by chronic administration of 15 mM levodopa (males: 6.55 ± 0.41D; females: 
5.24 ± 0.41D) or 15 mM levodopa with 3.75 mM carbidopa drops (males: 6.78 ± 0.16D; females: 5.33 ± 0.60D) 
following nine months of treatment (ANOVA F(2,27) = 1.471, p = 0.239).
Electroretinogram responses are not altered by topical application of levodopa: Chronic application of levo-
dopa (15 mM) or levodopa/carbidopa (15 mM/3.75 mM) over a 9-month period did not induce any permanent 
changes in recorded electroretinogram (ERG) waveforms (Supplementary Figure S-3) or waveform parameters 
(Fig. 8) following a 5 day washout period. Specifically, no differences occurred between treated and untreated ani-
mals in A-wave amplitude (Wilks’ Lambda = 0.763, F(2,25) = 1.314, p = 0.086), or latency (Wilks’ Lambda = 0.788, 
F(2,25) = 1.468, p = 0.181) or, B-wave amplitude (Wilks’ Lambda = 0.675, F(2,25) = 1.869, p = 0.061) or latency 
(Wilks’ Lambda = 0.690, F(2,25) = 1.752, p = 0.082), or the amplitude (Wilks’ Lambda = 0.748, F(2,25) = 1.219, 
p = 0.292) or latency (Wilks’ Lambda = 0.749, F(2,25) = 1.211, p = 0.297) of oscillatory potential 2. Furthermore, 
no significant differences arose in light adapted responses (Wilks’ Lambda = 0.498, F(2,25) = 1.458, p = 0.217).
Similarly, levodopa administration had no notable effect on ERG waveforms (Supplementary Figure S-4) or 
waveform parameters (Supplementary Figure S-5) in recordings performed 2 hours following topical levodopa 
administration to previously naïve mice.
Discussion
Intravitreal and topical application of levodopa slowed ocular growth and significantly inhibited the development 
of experimental myopia (FDM) in a dose-dependent manner. The EC50 values for both intravitreal injection 
and tropical application of levodopa were similar to those of atropine, the gold standard for pharmacological 
treatment of myopia in humans. Intravitreal injection of levodopa slowed the excessive ocular growth associated 
with FDM to a greater extent than that of topical application. However, the addition of carbidopa enhanced the 
effects of topically applied levodopa, similar to that seen during its systemic use for the treatment of neurological 
Figure 6. Plasma levels of levodopa and its metabolites. (A) Levodopa (B) dopamine. Data represents the 
mean ± standard error of the mean. Statistics denote difference to untreated controls; *p < 0.05, **p < 0.02, 
***p < 0.001 (n = 9 per treatment). TRACE denotes when several samples were detected (S/N > 3) but not 
quantifiable (S/N < 10); levodopa in eye drops and age-matched untreated control samples fell in this range in 
1 and 4 samples respectively, and dopamine in eye drops and age-matched untreated control samples fell in this 
range in 1 sample per group.
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disorders, by presumably inhibiting its premature break-down by the enzyme aromatic l-amino acid decarbox-
ylase (AAAD)29, and thus lowering the dose of levodopa required to achieve protection. Interestingly, the pro-
tective effects of systemic levodopa against the development of experimental myopia in guinea pigs have been 
reported to be inhibited by injection of carbidopa into the peribular space30, contrary to what would be expected 
from the existing literature surrounding the coadministration of levodopa and carbidopa.
The effectiveness of topically applied levodopa and levodopa:carbidopa was maintained over a period 
of 4 weeks (chronic treatment), which represents approximately one third of the ocular maturation period of 
chicks31,32 and the critical window in which eye growth is most susceptible to visual manipulation in this species32. 
As seen during acute treatment, levodopa’s effectiveness was significantly enhanced by co-administration with 
carbidopa. In contrast, the addition of the preservative and corneal penetrating agent BAK did not enhance the 
protective effects seen relative to levodopa alone.
Chronic application of levodopa, or levodopa:carbidopa, as a topical solution did not induce changes in those 
measures of ocular health examined in chicks (histology and cell survival, intraocular pressure, or normal ocu-
lar development (ocular biometry and refraction)) and mice (ERG recordings, histology and cell survival, and 
normal refractive development). The lack of alterations in ERG recordings in mice mirrors work in Parkinsonian 
patients, in which levodopa treatment does not alter normal ERG responses33 and has been shown to retrieve 
waveform parameters in subjects with abnormal ERG responses associated with depressed dopaminergic activity 
in Parkinson’s disease34–36. Furthermore, no alterations in normal ERG responses are observed following high 
doses of levodopa (200 mg)37,38. In accordance with a lack of change in the electrical activity of the retina, levo-
dopa did not induce alterations in retinal architecture or produce signs of cell stress/death (apoptosis). In agree-
ment with these findings, chronic levodopa administration has not been associated with ocular complications in 
patient populations33–38. This is consistent with the literature surrounding levodopa and cell health, as although 
levodopa has been reported to cause apoptosis in cultured neural tissue39, when administered in vivo, little tox-
icity has been demonstrated in neurologically normal40,41 or neurologically vulnerable42–44 animals (for review 
see45). Furthermore, clinical studies have indicated that chronic levodopa treatment is non-toxic to nigrostriatal 
dopaminergic neurons in humans46–48. Importantly, we report that levodopa does not appear to alter normal 
ocular development, and instead only becomes effective when administered to eyes in which the retinal dopamin-
ergic system is dysregulated by myopia induction.
Together, the findings of this study suggest that levodopa may be a potential therapeutic treatment for human 
myopia by acting to restore dopaminergic function. Based on recent clinical findings, topical application of levo-
dopa may also have potential for the treatment of other visual disorders in which dysregulation of dopaminergic 
system has been implicated and where systemic levodopa treatment has been shown to be beneficial, including; 
Figure 7. Comparison between levodopa and atropine dose response curves in chick. (A) Percent protection 
against the axial elongation and (B) myopic shift in refraction associated with FD in eyes treated with levodopa 
or atropine intravitreal injections. (C) Percent protection against the axial elongation and (D) myopic shift 
in refraction associated with FD in eyes treated with levodopa or atropine topical eye drops. Data represents 
mean ± standard error of the mean.
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amblyopia49, diabetic retinopathy50 and age-related macular degeneration (AMD)51. Levodopa has been in clini-
cal use for over five decades and is the primary treatment for neurological disorders, such as Parkinson’s disease, 
involving the dysregulation of the dopaminergic system (for review see28). Systemic administration of levodopa, 
as undertaken for Parkinson’s disease, is not appropriate for the treatment of myopia as it would lead to changes 
in dopaminergic activity not only within the eye, but within the brain and the rest of the body in an otherwise 
healthy developing child. Topical application of levodopa would maximise the amount of levodopa reaching the 
retina while minimising systemic distribution, lowering the dose required to achieve protection relative to sys-
temic administration. Accordingly, levodopa administered via eye drops did not significantly alter dopaminergic 
Figure 8. Effects of chronic (9-months) topical application of levodopa or levodopa/carbidopa on mouse 
electroretinogram responses. (A) A-wave amplitude; (B) A-wave latency; (C) B-wave amplitude; (D) B-wave 
latency; (E) Oscillatory potential 2 amplitude; (F) Oscillatory potential 2 latency. (G) Amplitude of responses in 
light adapted animals. (G) Latency of responses in light adapted animals. Data represents mean ± standard error 
of the mean.
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activity within the blood, particularly when compared to the elevated levels observed in spiked samples. This 
suggests that, when myopia inhibiting doses are applied to the eye, limited systemic distribution of levodopa 
occurs. Therefore, this approach minimises the likelihood of those side effects most commonly reported with 
long-term levodopa treatment which can be exacerbated at higher concentrations (such as motor fluctuations and 
dyskinesias28). There is currently no clinical data available on the use of topical levodopa, in ophthalmic prepa-
rations or elsewhere, so it is difficult to evaluate the degree to which levodopa eye drops may induce side effects 
arising from systemic distribution. Studies on systemic administration of levodopa in children with amblyopia 
have implicated side effects such as headaches, nausea, fatigue, mood changes, nightmares, emesis, dizziness, dry 
mouth and decreased appetite52. Elevated dopamine levels in the brain have been linked to attention deficit disor-
ders. However, whether these disorders are driven by increased dopamine release, or whether elevated dopamine 
levels are a consequence of the pharmacological treatment of these disorders is still under debate53. Levodopa 
has also been associated with cardiovascular effects54,55 and schizophrenia56,57 in a subset of individuals, although 
such an association requires further investigation. Our current data indicates that topical levodopa application 
did not lead to any notable side effects or adverse effects, however, care must always be taken when modulating 
dopaminergic activity.
The dose-response curve for atropine eye drops in this study correlated remarkably well with results observed 
in its clinical use (for review see58). Specifically, similar to the EC50 we report here (0.06% w/v), 0.05% w/v atro-
pine has been shown to slow myopia progression in children by roughly 60%59. This suggests that the animal 
pharmacological EC50 data correlates well with observed clinical outcomes. Therefore, as the dose curves for 
topically applied atropine and levodopa are markedly similar, this would suggest that the EC50 for levodopa may 
translate into clinical outcomes with a similar consistency to that of atropine, however this does not account for 
differences in the mechanism of action of levodopa and atropine.
While atropine is a well-validated tool for controlling the progression of myopia in humans, its side-effects 
at high doses60, the existence of a rebound effect after cessation of treatment61, uncertainties about its mode of 
action62, and the reported existence of non-responders, suggest that an alternative pharmacological treatment 
may be useful. These findings suggest that topical application of the naturally occurring compound levodopa, 
which has a well-documented history of use in humans, may be a viable candidate for future clinical treatment 
of myopia.
As excessive axial elongation is the root cause of pathological outcomes arising from myopia, and therefore 
the primary clinical target, more attention was afforded the ability of levodopa to attenuate axial elongation. In 
this study, as is commonly exhibited in animal models of myopia63–72, axial length and refraction data demon-
strate the same direction of change, despite differences in overall effect size, with no alterations were observed 
in other ocular components (corneal curvature, corneal thickness, anterior chamber depth, and lens thickness). 
Chicks were refracted in darkened rooms, however, cycloplegia was not induced as the required use of nicotinic 
antagonists, which are known to themselves inhibit experimental myopia64, could lead to a misrepresentation of 
the effectiveness of levodopa.
Conclusions. In chickens, manipulation of the dopaminergic system by intravitreal or topical admin-
istration of levodopa slows ocular growth and thereby inhibits the development of experimental myopia in a 
dose-dependent manner. Levodopa shows a similar potency to that of atropine, currently the primary phar-
macological treatment for myopia in humans. The addition of carbidopa significantly enhances the potency of 
topical levodopa, allowing its growth inhibiting effects to be maintained at much lower doses. Further, topically 
applied levodopa and levodopa/carbidopa remains effective over chronic treatment periods. Importantly, topical 
application of levodopa or levodopa:carbidopa did not alter visual function and ocular health in those parameters 
tested in chicks or mice. These findings indicate that levodopa may have potential as a therapeutic intervention 
for human myopia.
Methods
Overview. The effects of levodopa upon ocular growth were initially examined by testing the dose-dependent 
effects of intravitreal and topical application of levodopa against the development of form-deprivation myopia 
(FDM) in chicks over a period of 4 days. Within this 4 day treatment period, the effects of intravitreal and topical 
atropine, as well as ways to increase the effectiveness of topical levodopa through the addition of carbidopa or 
DMSO, were also studied in the chick form-deprivation model.
To complement the above work, the effects of topical levodopa and levodopa/carbidopa against the develop-
ment of FDM were examined in chicks over a chronic, 4 week period, which was combined with an analysis of 
ocular safety focusing on retinal health, refractive development, axial elongation, and interocular pressure.
To show that levodopa treatment altered dopamine levels within the eye, but not systemically, catecholamine 
levels were quantified in the vitreous body and blood samples. This analysis was undertaken in form-deprived 
chicks following a single treatment of levodopa. Chicks were not analysed after four days or four weeks in this 
initial experiment to remove the compounding factor of potential adaptation with time.
With a focus on possible clinical use in humans, ocular safety findings from chicks were translated to a mam-
malian model (C56BL/6 J mice). Topical eye drops were administered to otherwise untreated mice for a period of 
9 months to complement the avian data and examine the effects of chronic treatment on visual function, retinal 
health, and normal refractive development this mammalian model.
Animal housing. Day-old male White-Leghorn chickens were obtained from Barter & Sons Hatchery 
(Horsley Park, NSW, Australia). Chicks were kept in temperature-controlled rooms and were given five days to 
adjust to their surroundings before the experiments commenced. Chicks had access to unlimited amounts of food 
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and water and were kept under normal laboratory lighting (500 lux, fluorescent lights) on a 12:12 hour light:dark 
cycle with lights on at 9:30am and off at 9:30 pm.
Mice (C56BL/6 J) were obtained from the University of Canberra breeding colony. Mice were kept five to a 
cage (males and females caged separately) in individually ventilated caging, with experiments commencing at 8 
weeks of age. Mice were housed at 23 °C on a 12:12 hour light:dark cycle (8am:8 pm; 500lux fluorescent lights) and 
had access to unlimited amounts of food and water.
Experimental procedures were approved by the University of Canberra Animal Ethics Committee under the 
ACT Animal Welfare Act 1992 (project number CEAE 16–05) and conformed to the ARVO Statement for the Use 
of Animals in Ophthalmic and Vision Research.
Experimental methods – short-term (4 day) effectiveness of levodopa in chicks. Standard exper-
imental structure. Myopia was induced by placing a translucent diffuser (FDM) over the treated (left) eye as 
previously described to induce form-deprivation myopia (FDM)25. Specifically, Velcro mounts were fitted around 
the left eye on the day prior to the commencement of treatment. On the following day, a diffuser fitted to a match-
ing Velcro ring was mounted over the eye. The right eyes remained untreated to serve as an internal contralateral 
control.
For drug administration, chicks were given a once daily 10 μL intravitreal injection (9:30am), or two 40 μL 
topical eye drops twice daily (9:30am and 2 pm), of their respective drug solution (levodopa, levodopa/cari-
bodpa, levodopa/DMSO or atropine) to their diffuser-treated (left) eye for a period of four days. For intravitreal 
administration, chicks were anaesthetised under light isoflurane (5% in 1 L of medical grade oxygen per minute, 
Veterinary Companies of Australia, Kings Park, NSW, Australia) using a vaporiser gas system (Stinger Research 
Anaesthetic Gas Machine (2848), Advanced Anaesthesia Specialists, Payson, Arizona, USA).
For all preparations, levodopa (Sigma Aldrich, D9628) was dissolved fresh in a solution containing 0.1% w/v 
ascorbic acid in 1x phosphate-buffered saline (PBS). Immediately prior to administration, the pH of the levo-
dopa solution was adjusted to 5.5. For treatments containing carbidopa (Sigma Aldrich, C1335), levodopa and 
carbidopa were combined at a 4:1 ratio and dissolved as per outlined above for levodopa alone. For treatment 
with dimethyl sulfoxide (DMSO), levodopa was dissolved as above with the addition of 10% v/v DMSO (Sigma 
Aldrich, D8418). Atropine solutions comprised of atropine monosulfate (Abcam, A10236) dissolved in 1xPBS 
(pH of 6).
Refraction and ultrasonography measurements, to assess myopia development, were undertaken the day prior 
to the commencement of treatment and on the final day of the experimental period as previously described25. 
Refraction was measured using automated infrared photoretinoscopy (system provided courtesy of Professor 
Frank Schaeffel, University of Tuebingen, Germany). Measurements were taken for both treated (left) and con-
tralateral control (right) eyes, with refractive values representing the mean spherical equivalent of 10 meas-
urements per eye. For axis alignment, the Purkinje image was centered within the pupil to obtain the correct 
refractive axis, with illumination levels within the room held at less than 5 lux to avoid light reflections in the 
pupil arising from aberrant sources. Axial length was measured, on chicks anesthetised as above, using A-scan 
ultrasonography (Biometer AL-100; Tomey Corporation, Nagoya, Japan). For short-term experiments, ocular 
parameters for the drug treated eyes (Supplementary Table S-1) were compared against diffuser-treated animals 
without levodopa (FDM Only, n = 26), age-matched untreated control animals (n = 17), and their contralateral 
control eyes.
Levodopa dose-response curve (intravitreal injections). To investigate whether levodopa, when introduced 
directly to the retina (Supplementary Table S-1A), can prevent FDM in chickens, animals were divided between 
the following groups:
 1. Fitted with a translucent diffuser – daily intravitreal injection of levodopa at one of the following concen-
trations: 0.15 mM (n = 8), 1.5 mM (n = 15), 15 mM (n = 15), 75 mM (n = 8);
 2. Fitted with a translucent diffuser – daily intravitreal injection of the vehicle solution (0.1% w/v ascorbic 
acid in 1xPBS, pH 5.5; n = 10);
 3. No translucent diffuser fitted – daily intravitreal injection of levodopa (15 mM, n = 10).
Levodopa dose-response curve (topical drops). To establish whether a protective effect against the develop-
ment of FDM in chicks persists when levodopa is administered as a topical solution to the eye (Supplementary 
Table S-1B), and whether this delivery of levodopa can be enhanced by the addition of carbidopa (to prevent 
premature metabolism) or DMSO (to enhance corneal penetration), chicks were divided between the following 
groups:
 1. Fitted with a translucent diffuser – topical application of levodopa at one of the following concentrations: 
0.15 mM (n = 18), 1.5 mM (n = 18), 15 mM (n = 14), 45 mM (n = 9);
 2. Fitted with a translucent diffuser – topical administration of 15 mM levodopa with 3.75 mM carbidopa 
(n = 14), or 15 mM levodopa in 10% DMSO (n = 9);
 3. Fitted with a translucent diffuser – topical application of the vehicle solution alone (0.1% w/v ascorbic acid 
in 1xPBS, pH 5.5; n = 11);
 4. No translucent diffuser fitted – topical application of levodopa (15 mM, n = 15).
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Due to solubility limits, levodopa at a concentration of 75 mM or higher will not remain in solution for longer 
than 10 minutes at a pH 5.5. Therefore, a 45 mM solution, which sat at the upper solubility limit of levodopa at pH 
5.5, was the highest dose tested for topical eye drops.
For all further analyses of levodopa, a concentration of 15 mM was used. The higher dose of 45 mM was not 
used for further analyses as although it shows a stronger treatment effect, it sits at the solubility limit of this 
compound.
Following 4 days of topical treatment with a 15 mM levodopa solution into form-deprived eyes, corneal thick-
ness (DGH Pachmate 2 pachymeter, DGH Technology Inc., USA) and corneal curvature were measured to deter-
mine any effects on the refractive surface. Corneal curvature (measured as the radius of curvature) was examined 
following the procedure outlined in Troilo & Wallman73 using a keratometer (Topcon OM-4) fitted with a + 8D 
lens to adapt the system to the highly curved chick cornea, and calibrated by measuring curvatures of chrome 
balls of known diameters (2–8 mm).
Effectiveness of levodopa relative to atropine (intravitreal and topical application). To examine the effectiveness 
of levodopa when compared to that of atropine, the most widely used pharmacological treatment for myopia in 
humans, a dose-response analysis of atropine was also undertaken (Supplementary Table S-1C,D). For this, chicks 
were divided between the following groups:
 1. Fitted with a translucent diffuser – intravitreal injection of atropine at one of the following concentrations: 
0.0015 mM (n = 12), 0.015 mM (n = 12), 0.15 mM (n = 12), 1.5 mM (n = 12), 15 mM (n = 12);
 2. Fitted with a translucent diffuser – topical application of atropine at one of the following concentrations: 
0.015 mM (n = 6), 0.15 mM (n = 6), 1.5 mM (n = 6), 15 mM (n = 6).
Experimental methods – long-term (4 week) effectiveness and safety of levodopa in chicks. To 
establish the effectiveness of levodopa over a more chronic treatment period, myopia was induced, and topical 
levodopa administered to chicks as outlined for 4 day treatments, for a period of 4 weeks. Refraction and ultra-
sonography measurements were undertaken prior to the commencement of the experiment and at the end of each 
proceeding week as outlined for short-term experiments. In addition, corneal thickness (measured as above in 4 
day experiments) and intraocular pressure (Icare TA01i tonometer, Icare, Finland) of chicks were also measured 
alongside the final biometric measurements after 4 weeks of treatment. Ocular parameters for the drug treated 
eyes (Supplementary Table S-1B) were compared against diffuser-treated animals without levodopa (FDM Only, 
n = 18) and age-matched untreated control animals (n = 18).
Over this 4 week period, chicks were administered eye drops to both eyes, with the left eye fitted with a trans-
lucent diffuser and the right eye receiving no optical treatment. Levodopa treatment animals were divided into 3 
groups (Supplementary Table S-1B):
 1. Fitted with a translucent diffuser – topical application of 15 mM levodopa (n = 18);
 2. Fitted with a translucent diffuser – topical application of 15 mM levodopa/3.75 mM carbidopa (n = 12);
 3. Fitted with a translucent diffuser – topical application of 15 mM levodopa in 0.1% w/v benzalkonium chlo-
ride (BAK, n = 6).
Levodopa and levodopa/carbidopa solutions were prepared as outlined for 4 day treatments. For treatment 
with BAK, levodopa was dissolved as above with the addition of 0.1% w/v BAK (Sigma Aldrich, 12060). BAK was 
used in place of DMSO due to its higher frequency of use in topical ophthalmic preparations as an antimicrobial 
and corneal penetrating agent74. Following final measurements, chicks were sacrificed and tissue prepared for 
histological analysis following procedures outlined by Karouta & Ashby25 (see Supplementary Methods for full 
details). Retinal sections were treated with toluidine blue to examine retinal architecture or underwent TUNEL 
analysis to determine whether the retina was undergoing apoptosis.
The effects of levodopa treatment on catecholamine levels in previously naïve chicks. Ocular 
dopamine levels. To show that levodopa treatment altered dopamine levels within the eye, catecholamine levels 
were quantified in the vitreous body samples. This analysis was undertaken in form-deprived chicks following a 
single treatment of levodopa. Chicks were not analysed after four days or four weeks in this initial experiment to 
remove the compounding factor of potential adaptation with time.
Vitreous samples were measured using high performance liquid chromatography tandem mass spectrometry 
(LC-MS-MS) following a protocol adapted from Perez-Fernandez et al.75 (see Supplementary Methods for full 
details). Samples were collected 1 hour after drug treatments and the fitment of diffusers to previously naïve 
chicks. Treatment commenced at lights on (9:30am), with chicks broken into the following groups:
 1. Fitted with a translucent diffuser – intravitreal injection of levodopa (15 mM, n = 5);
 2. Fitted with a translucent diffuser – no intravitreal or topical application of the drug (myopia control group 
(FD Only), n = 5);
 3. Age-matched untreated control animals (n = 5).
Systemic (blood) dopamine levels. To examine if levodopa is systemically distributed following topical appli-
cation, and whether topical levodopa application alters dopamine levels systemically, blood samples from 
chicks treated with 15 mM drops were measured using an LC-MS-MS following a protocol adapted from 
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Perez-Fernandez et al.75 (see Supplementary Methods for full details). Samples were collected 15 minutes after 
drug treatment to examine the maximum amount of systemically distributed levodopa, with topical application 
occurring at lights on (9:30am). Chicks were divided into the following two groups:
 1. Topical application of levodopa (15 mM, n = 9);
 2. Age-matched untreated control animals (n = 9);
In a concurrent experiment, aliquots of blood taken from the above age-matched untreated animals were 
spiked with a 15 mM levodopa solution. The volume of the spike was adjusted relative to the volume of blood 
taken. That is, at this age the chicken contains 8 mL of blood76. From this 8 mL total blood volume, 1 mL aliquots 
were taken, which represents 12.5% of the total blood volume of the animal. Therefore, 12.5% of the topical 
volume, which is normally 0.08 mL, was added to the blood. Spiked blood samples were then analysed at two 
timepoints (time zero (n = 9) and following 15 minutes incubation at room temperature (n = 9)). This process 
simulated the maximum levodopa that should be detectable systemically if the entirety of the topical drops were 
absorbed into the circulation.
Mammalian analysis of safety (mouse). Chronic levodopa treatment. To investigate the safety 
of levodopa administration in a mammalian model, C57BL/6 J mice were divided into 3 treatment groups 
(Supplementary Table S-1E) and chronically treated (9 months):
 1. Age-matched untreated controls (5 males, 5 females);
 2. Topical levodopa treatment (15 mM) to otherwise untreated eyes (5 males, 5 females);
 3. Topical levodopa/carbidopa treatment (4:1, 15 mM:3.75 mM respectively) to otherwise untreated eyes (5 
males, 5 females).
Commencing at 8 weeks of age, mice were administered one 10 µL drop of their respective drug solution 
(Supplementary Table S-1E) to each eye once daily at 11am or left untreated, for a period of 9 months. Each day, a 
health score analysis was undertaken that examined weight, fur condition, activity, respiratory rate, gait, interac-
tions with casemates, temperament, faeces, posture, and external condition of the eye.
Refraction was measured at the completion of the 9-month period using infrared photorefraction as outlined 
above for chickens, with the 75 mm F/1.4 C-type lens with a 5 mm extension tube replaced with a 50 mm F/1.4 
C-type lens with a 10 mm extension tube to account for the smaller eye of the mouse. Following a further 5 days 
of no topical treatment (washout period), ERG measurements (see Supplementary Methods for full details) were 
undertaken before the mice were sacrificed by an overdose of isoflurane anaesthetic, with eyes immediately enu-
cleated for base histology and TUNEL analysis (see Supplementary Methods for full details).
In addition to examining ERG responses following chronic treatment (9 months) with levodopa, we also 
examined whether retinal function is immediately altered following daily levodopa application. To do this, 
previously untreated mice of an equivalent age (9 months) to those treated above were administered one drop 
of 15 mM levodopa to each eye (n = 3 males, n = 2 females). Two hours after drops were given, during which 
time the animals remained in the dark, ERG recordings were performed and compared to those of age-matched 
untreated control animals (n = 3 males, n = 2 females).
Statistical analysis. All values reported represent the mean ± the standard error of the mean. Before ana-
lysing the effect of treatment, all data were first tested for normality and homogeneity of variance (Shapiro-Wilk 
test). Following this, the effect of short-term treatment was analysed via a one-way univariate analysis of variance 
(ANOVA) followed by a student’s unpaired t-test, with Bonferroni correction for multiple testing, for analysis of 
specific between group effects. ERG responses and the effects of long-term treatment were analysed using a repeat 
measures multivariate analysis of variance (MANOVA) followed by a student’s unpaired t-test, with Bonferroni 
correction for multiple testing, for analysis of specific between group effects. All analyses were undertaken in IBM 
SPSS Statistics package 23 with a statistical cut-off of 0.05.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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